Please login to the form below

Not currently logged in
Email:
Password:

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy

ExelixisCalifornia, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.

In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.

Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.

“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”

Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.

He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.

11th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics